Search clinical trials for: ridaforolimus dalotuzumab

Total 132 results

Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)

Neoplasms
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Breast Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus in Patients With Hepatic Insufficiency (MK-8669-046)

Hepatic Insufficiency | Healthy Volunteers
Merck Sharp & Dohme LLC

Completed

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Neoplasm
Merck Sharp & Dohme LLC

Terminated

A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)

Solid Tumors
Merck Sharp & Dohme LLC

Completed

A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)

Advanced Solid Tumors
Medinol Ltd.

Not yet recruiting

First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease (CHAMPIONSHIP)

Popliteal Artery Stenosis | Superficial Femoral Artery Stenosis
Merck Sharp & Dohme LLC

Completed

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Multiple Myeloma | Solid Tumor
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Neoplasm
Merck Sharp & Dohme LLC
University of Colorado, Denver; Memorial Sloan Kettering Cancer Center; H. Lee... and other collaborators

Completed

A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)

Solid Tumors
Medinol Ltd.

Completed

BIONICS Israel Trial

Stenosis

Israel
Medinol Ltd.

Completed

MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR)

de Novo or Restenosis Lesions

Japan
Merck Sharp & Dohme LLC

Completed

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Breast Neoplasms
Medinol Ltd.

Completed

BIONICS 38 mm Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial

Coronary Stenosis

Israel
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
NCIC Clinical Trials Group
Ariad Pharmaceuticals

Completed

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Endometrial Cancer

Canada
Medinol Ltd.

Completed

BIONICS - Pharmacokinetics (PK) Trial (BIONICS)

Heart Disease

United States
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)

Advanced Cancers
Medinol Ltd.

Not yet recruiting

IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

Coronary Artery Disease | Coronary Stenosis
Angela Taber MD
The Miriam Hospital; Rhode Island Hospital; Memorial Hospital of Rhode Island; Roger...

Terminated

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Non-Small Cell Lung Cancer

United States
Medinol Ltd.

Completed

BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) In Coronary Stenosis Trial

Myocardial Ischemia | Cardiovascular Diseases | Coronary Disease | Coronary Stenosis

Israel
The University of Texas Health Science Center at...
Merck Sharp & Dohme LLC

Withdrawn

Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Bristol-Myers Squibb
AbbVie

Completed

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Smoldering Multiple Myeloma

United States
Abbott
Bristol-Myers Squibb

Terminated

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

Multiple Myeloma

United States
Medinol Ltd.

Recruiting

IonMAN Trial- First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (IonMAN)

Cardiovascular Diseases | Coronary Disease | Non-ST Elevated Myocardial Infarction | Coronary Stenosis

Israel, Brazil
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Seagen Inc.
Genentech, Inc.

Completed

A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin Lymphoma

United States
Seagen Inc.
Genentech, Inc.

Completed

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Prostate Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)

Sarcoma
Seagen Inc.
Genentech, Inc.

Completed

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Multiple Myeloma

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Terminated

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)

Cancer, Advanced
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Prostate Cancer

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Lymphoma | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancies | Myeloid Metaplasia

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Lymphoma | Multiple Myeloma | Tumors

United States
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Endometrial Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Sarcoma, Soft Tissue | Osteosarcoma | Leiomyosarcoma | Liposarcoma | Metastases
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Metastatic or Locally Advanced Cancer
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) (SUCCEED)

Metastatic Soft-Tissue Sarcomas | Metastatic Bone Sarcomas
Yale University
GlaxoSmithKline

Recruiting

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Completed

A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Breast Cancer | Breast Neoplasms
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Solid Tumor

3

Subscribe